USPTO Patent Application: CARs for Hidradenitis Suppurativa Treatment
Summary
The USPTO has published a patent application (US20260083777A1) filed by Sonoma Biotherapeutics, Inc. The application describes chimeric antigen receptors (CARs) designed to target citrullinated polypeptides for the treatment of hidradenitis suppurativa.
What changed
This document is a publication of a US patent application (US20260083777A1) filed on September 18, 2023, by Sonoma Biotherapeutics, Inc. The application details chimeric antigen receptors (CARs) that recognize citrullinated polypeptides, specifically mentioning citrullinated vimentin, which are found in skin lesions of patients with hidradenitis suppurativa. The invention also covers T cells, particularly Treg cells, engineered to express these CARs, and their administration for treating the condition.
As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signifies potential future developments in therapeutic treatments for hidradenitis suppurativa. Companies involved in pharmaceutical research, biotechnology, and the development of treatments for autoimmune or dermatological conditions should be aware of this filing as it may impact intellectual property landscapes and future market competition.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CITRULLINATED ANTIGEN-SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR TARGETING REGULATORY T CELLS TO TREAT HIDRADENITIS SUPPURATIVA
Application US20260083777A1 Kind: A1 Mar 26, 2026
Assignee
Sonoma Biotherapeutics, Inc.
Inventors
Leonard DRAGONE, Joshua BEILKE
Abstract
Disclosed herein are chimeric antigen receptors (CARs) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, are expressed in the skin lesions of subjects with hidradenitis suppurativa. Further disclosed are T cells, and in particular, Treg cells that express these CARs. Administration of these CAR-T cells is useful in the treatment of hidradenitis suppurativa.
CPC Classifications
A61K 35/17 A61K 40/11 A61K 40/31 A61K 40/416 C07K 14/535 C07K 14/7051 C07K 14/70517 C07K 14/70521 C07K 16/18 C12N 5/0637 A61K 2239/13 A61K 2239/17 A61K 2239/21 C07K 2317/53 C07K 2317/565 C07K 2317/622 C07K 2319/02 C07K 2319/03 C12N 2510/00
Filing Date
2023-09-18
Application No.
19112106
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.